Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Monday as it is currently trading at $69.78, above its previous 52-week high of $69.70 with 205,821 shares traded as of 12:01 p.m. ET. Average volume has been 595,700 shares over the past 30 days.
By TheStreet Wire ,

NEW YORK (

TheStreet

) --

Salix Pharmaceuticals

(Nasdaq:

SLXP

) hit a new 52-week high Monday as it is currently trading at $69.78, above its previous 52-week high of $69.70 with 205,821 shares traded as of 12:01 p.m. ET. Average volume has been 595,700 shares over the past 30 days.

Salix has a market cap of $4.24 billion and is part of the health care sector and drugs industry. Shares are up 71% year to date as of the close of trading on Friday.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates

Salix

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full

Salix Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

.

null

Loading ...